BiotechTube
Omics Edge

Omics Edge

San Diego, United States· Est.
omicsedge.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

Omics Edge operates as a B2B genomics infrastructure provider, offering a HIPAA/GDPR-compliant platform for white-label genetic testing and analysis. Spun out from SelfDecode, the company leverages a team of over 60 experts to deliver clinically validated polygenic risk scores and a comprehensive suite of bioinformatics tools via API or turnkey solutions. It serves a global clientele, including health tech firms, hospitals, and nutrition brands, with capabilities spanning from ancestry and carrier status to whole-genome sequencing and fulfillment, requiring no minimum volume commitments.

AI / Machine LearningGenetics & Genomics

Technology Platform

Cloud-based bioinformatics platform and API offering ancestry-informed AI-driven polygenic risk scores, genetic imputation, and analysis of 200M+ variants for over 1,500 customizable white-label genetic reports. Supports genotyping, exome, and whole-genome sequencing with integrated blood test and environmental factor analysis.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The rapid growth of precision medicine and digital health creates massive demand for scalable genomic infrastructure.
Expansion into integrated health platforms combining genetics with wearables and electronic health records presents a significant growth avenue.
Increasing clinical adoption of polygenic risk scores and pharmacogenomics in standard care opens doors for deeper partnerships with hospitals and health systems.

Risk Factors

Intense competition from large genomic firms and in-house bioinformatics teams at major health institutions poses a constant threat.
Evolving and fragmented global regulations on genetic data privacy (GDPR, HIPAA) and clinical validity create compliance complexity and potential liability.
Market saturation or a slowdown in consumer demand for genetic testing could negatively impact its B2B clients and, consequently, its own revenue.

Competitive Landscape

Omics Edge competes in the B2B genomics space against large sequencing and array providers (e.g., Illumina, Thermo Fisher) offering their own analysis tools, specialized bioinformatics software companies (e.g., DNAnexus, Seven Bridges), and other API-focused genomics providers. Its differentiation lies in its specific focus on white-label, clinically validated polygenic risk scores, a vast report library, and flexible integration models with global fulfillment, targeting non-genomics companies wanting to enter the personalized health market.

More companies in Diagnostics & Precision Medicine →More companies in United States →